Verubecestat

• Description :

  Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease[1][2].

• Product Name Alternative :

  MK-8931

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Beta-secretase

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Verubecestat.html

• Purity :

  99.56

• Solubility :

  DMSO : ≥ 35 mg/mL

• Smiles :

  O=C(C1=NC=C(F)C=C1)NC2=CC=C(F)C([C@@](C3)(C)N=C(N)N(C)S3(=O)=O)=C2

• Molecular Formula :

  C17H17F2N5O3S

• Molecular Weight :

  409.41

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Yan R, et al. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13.|[2]Scott JD, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931) -A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer'sDisease. Med Chem. 2016 Dec 8;59 (23) :10435-10450.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• Isoform :

  BACE1; BACE2

• CAS Number :

  [1286770-55-5]